| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5748
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5041
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 |
| filingDate |
2012-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2019-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102027448-B1 |
| titleOfInvention |
Hsp90 combination therapy |
| abstract |
The present invention relates to (a) inhibitors of Hsp90 or inhibitors of Hsp90 under conditions that allow a sample containing cancer cells from a subject to bind one or more cancer pathway components present in the sample to an Hsp90 inhibitor or analog, homologue or derivative of Hsp90 inhibitor. Contacting with an analog, homologue or derivative of; (b) detecting a pathway component bound to an Hsp90 inhibitor or analog, homologue or derivative of the Hsp90 inhibitor; (c) analyzing the route component detected in step (b) to identify a route comprising the component detected in step (b) and additional components of this route; (d) selecting an inhibitor of the pathway or pathway component identified in step (b), a component of the cancer-associated pathway or cancer-associated pathway for co-administering an inhibitor of Hsp90 to a subject suffering from cancer It relates to a method of selecting an inhibitor of. The invention further relates to methods of treating cancer patients by co-administering inhibitors of Hsp90 and inhibitors of cancer-associated pathways or components thereof. |
| priorityDate |
2011-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |